Evidence map›Paper›PMID 39704740›Full record

ReviewCEN case reports2025

Granulomatosis with polyangiitis with rapidly progressive glomerulonephritis treated with a multipronged approach-a case based review.

Ujjwal Madan, Vishesh Goel, Jignesh Shah, Hameed Ahmad, Clarissa Cassol, Amr Edrees

Abstract readCase ReportsReview
In one paragraph

Review in CEN case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ujjwal MadanDivision of Internal Medicine, University of Missouri, Kansas City, MO, 64108, USA. ujjwalmadan96@gmail.com.ORCID 0000-0001-5368-4280
Vishesh GoelDivision of Internal Medicine, Lady Hardinge Medical College, New Delhi, 110001, India.
Jignesh ShahDivision of Nephrology, University of Missouri, Kansas City, MO, 64108, USA.
Hameed AhmadDivision of Nephrology, University of Missouri, Kansas City, MO, 64108, USA.
Clarissa CassolNephropathologist, Arkana Laboratories, Little Rock, AR, 72211, USA.
Amr EdreesDivision of Rheumatology, University of Missouri, Kansas City, MO, 64108, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Granulomatosis with polyangiitis is an ANCA-associated vasculitis that involves small to medium-sized vessels. The extent of renal involvement varies, which is also associated with disease prognosis, with aggressive renal involvement having worse outcomes. Rapidly progressive glomerulonephritis with severe inflammatory features and extensive crescent formation can be challenging to treat. Usually, induction regimes utilize a combination of pulse dose methylprednisolone followed by rituximab or cyclophosphamide. Resistant diseases pose additional treatment challenges, and individualized treatment regimens have been described without accumulated outcome data. Cyclophosphamide, rituximab, azathioprine, methotrexate, and mycophenolate with or without plasmapheresis have been variably used, but there is a lack of consensus on a standardized regime in literature. Our case adds to the existing literature on the treatment-refractory granulomatosis with polyangiitis, which was treated with high-dose corticosteroid in combination with rituximab, low-dose cyclophosphamide, plasmapheresis, and brief use of hemodialysis. It also reiterates that the use of a variety of low-dose cyclophosphamide with rituximab could be beneficial for treatment-refractory cases or patients with severe renal involvement, in addition to better tolerance with low dose cyclophosphamide in comparison with full-dose cyclophosphamide.

Indexed as

GlomerulonephritisGranulomatosis with PolyangiitisCyclophosphamideDisease ProgressionDrug Therapy, CombinationHumansImmunosuppressive AgentsMethylprednisolonePlasmapheresisRenal DialysisRituximabTreatment OutcomeCyclophosphamideImmunosuppressive AgentsMethylprednisoloneRituximabANCA vasculitisCyclophosphamidePlasmapheresisRituximabTreatment refractory granulomatosis with polyangiitis

Identifiers

PMID39704740
PMCPMC12307261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.